HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Robeson, W. Articles by Eidelberg, D. Search for Related Content PubMed PubMed Citation Articles by Robeson, W. Articles by Eidelberg, D.

Dosimetry of the Dopamine Transporter Radioligand ¹⁸F-FPCIT in Human Subjects

Center for Neurosciences, North Shore University Hospital, Manhasset, New York

This study was designed to evaluate the radiation dosimetry in human subjects for a new radiopharmaceutical, N-(3-¹⁸F-fluoropropyl)-2ß-carbomethoxy-3ß-(4-iodophenyl)nortropane (¹⁸F-FPCIT). The goal was to determine a limiting dose consistent with accepted guidelines for use in clinical studies and to compare the radiation burden with other agents such as ¹²³I-FPCIT, ¹⁸F-fluorodopa, and ¹⁸F-FDG. Methods: Dynamic PET scans of the urinary bladder were obtained in 6 subjects; 2 subjects had brain scans and 5 subjects had scans of the thorax or abdomen. Regions of interest were placed over composite images of each organ for which activity was visualized to generate time–activity curves. Doses were calculated from residence times using the MIRDOSE3 program. Results: The critical organ for dosimetry is the urinary bladder wall with a dose of 0.0586 ± 0.0164 mGy/MBq. The dose comes primarily (97.2%) from activity in the urinary bladder contents. The dose is lower than any of the other agents used commonly in PET to assess dopaminergic function. The effective dose equivalent (0.0120 mGy/MBq) is also lower than comparable compounds. Conclusion: ¹⁸F-FPCIT has favorable dosimetry when compared with other agents used to study dopaminergic function. Doses as high as 853 MBq (23 mCi) may be given to adult patients and remain within accepted guidelines.

Key Words: N-(3-fluoropropyl)-2ß-carbomethoxy-3ß-(4-iodophenyl)nortropane • dosimetry • PET • dopamine transporter

This article has been cited by other articles:

				K. Van Laere, M. Koole, S. M. Sanabria Bohorquez, K. Goffin, I. Guenther, M. J. Belanger, J. Cote, P. Rothenberg, I. De Lepeleire, I. D. Grachev, et al. Whole-Body Biodistribution and Radiation Dosimetry of the Human Cannabinoid Type-1 Receptor Ligand 18F-MK-9470 in Healthy Subjects J. Nucl. Med., March 1, 2008; 49(3): 439 - 445. [Abstract] [Full Text] [PDF]